secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-031701
Event type: earnings
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio Q1 net loss $24.2M ($0.22/sh); advancing tibulizumab Phase 2 trials
----------------------------------------------------------------------------

- Net loss of $24.2M ($0.22 per share) vs. $17.4M ($0.19) in Q1 2025.
- R&D expenses $14.7M, up from $10.5M, driven by tibulizumab Phase 2 programs.
- Cash $225.6M as of March 31, 2026, expected to fund operations through at least end of 2028.
- Phase 2 TibuSHIELD (HS) on track for topline data Q4 2026; TibuSURE (SSc) data expected H1 2027.
- Completed $144M public offering in February 2026; appointed new CEO and two board members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000162828026031701/0001628280-26-031701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000162828026031701/zura-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-031701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer